



2016 Financial Calendar

Paris, France, December 10th, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced its financial reporting schedule for 2016.

Financial publications will be issued after the market close. This schedule is indicative and subject to change.

- Half-year report on the liquidity contract: January 7, 2016
- 2016 Full-year Results: March 15, 2016
- Publication of the 2016 Financial Annual Report: April 28, 2016
- Annual General Meeting: June 24, 2016
- Half-year report on the liquidity contract: July 7, 2016
- 2016 Half-year Results: September 20, 2016
- Publication of the 2016 Financial Half-Year Report: September 28, 2016

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.

Follow us on Twitter [@ABIVAX_](https://twitter.com/ABIVAX_)

Contacts

Investor relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 09 63

Citigate Dewe Rogerson

Lucie Larguier
abivax@citigate.fr
+33 1 53 32 84 75

Life Sci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press relations

ALIZE RP

Caroline Carmagnol and Florence Portejoie
abivax@alizerp.com
+33 6 64 18 99 59 / + 33 1 44 54 36 64